JP7049683B2 - トラピジルを使用する錐体外路症候群の処置 - Google Patents

トラピジルを使用する錐体外路症候群の処置 Download PDF

Info

Publication number
JP7049683B2
JP7049683B2 JP2019502544A JP2019502544A JP7049683B2 JP 7049683 B2 JP7049683 B2 JP 7049683B2 JP 2019502544 A JP2019502544 A JP 2019502544A JP 2019502544 A JP2019502544 A JP 2019502544A JP 7049683 B2 JP7049683 B2 JP 7049683B2
Authority
JP
Japan
Prior art keywords
per day
trapidil
pharmaceutically acceptable
acid
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019502544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510826A (ja
JP2019510826A5 (enExample
Inventor
ボードバー，アーラッシュ
Original Assignee
シノピア バイオサイエンシーズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シノピア バイオサイエンシーズ，インク． filed Critical シノピア バイオサイエンシーズ，インク．
Publication of JP2019510826A publication Critical patent/JP2019510826A/ja
Publication of JP2019510826A5 publication Critical patent/JP2019510826A5/ja
Priority to JP2022044284A priority Critical patent/JP7794668B2/ja
Application granted granted Critical
Publication of JP7049683B2 publication Critical patent/JP7049683B2/ja
Priority to JP2024041690A priority patent/JP2024095682A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catching Or Destruction (AREA)
JP2019502544A 2016-04-04 2017-04-03 トラピジルを使用する錐体外路症候群の処置 Active JP7049683B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022044284A JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置
JP2024041690A JP2024095682A (ja) 2016-04-04 2024-03-15 トラピジルを使用する錐体外路症候群の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317983P 2016-04-04 2016-04-04
US62/317,983 2016-04-04
PCT/US2017/025788 WO2017176652A2 (en) 2016-04-04 2017-04-03 Treating extrapyramidal syndrome using trapidil

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022044284A Division JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置

Publications (3)

Publication Number Publication Date
JP2019510826A JP2019510826A (ja) 2019-04-18
JP2019510826A5 JP2019510826A5 (enExample) 2020-05-14
JP7049683B2 true JP7049683B2 (ja) 2022-04-07

Family

ID=60001402

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019502544A Active JP7049683B2 (ja) 2016-04-04 2017-04-03 トラピジルを使用する錐体外路症候群の処置
JP2022044284A Active JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置
JP2024041690A Pending JP2024095682A (ja) 2016-04-04 2024-03-15 トラピジルを使用する錐体外路症候群の処置

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022044284A Active JP7794668B2 (ja) 2016-04-04 2022-03-18 トラピジルを使用する錐体外路症候群の処置
JP2024041690A Pending JP2024095682A (ja) 2016-04-04 2024-03-15 トラピジルを使用する錐体外路症候群の処置

Country Status (10)

Country Link
US (4) US10350212B2 (enExample)
EP (1) EP3442538B1 (enExample)
JP (3) JP7049683B2 (enExample)
CN (2) CN109310700A (enExample)
AU (1) AU2017246334C1 (enExample)
CA (1) CA3054674A1 (enExample)
DK (1) DK3442538T3 (enExample)
ES (1) ES3039958T3 (enExample)
FI (1) FI3442538T3 (enExample)
WO (1) WO2017176652A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3054674A1 (en) 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
JP2021532098A (ja) 2018-07-19 2021-11-25 インペル ニューロファーマ インコーポレイテッド パーキンソン病の治療のためのレボドパおよびドーパデカルボキシラーゼ阻害剤の呼吸管路送達
EP4069239A4 (en) * 2019-12-02 2023-11-29 Sinopia Biosciences, Inc. Treating cognitive disorders using trapidil
IL296788A (en) * 2020-03-26 2022-11-01 Sinopia Biosciences Inc Isotopically labeled trepidil histories
WO2024053728A1 (ja) * 2022-09-09 2024-03-14 住友ファーマ株式会社 対象の状態の予測およびその応用
CN116754348B (zh) * 2023-06-06 2024-03-08 华北理工大学 基于zif-8-90材料的泡腾片、其制备方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US20070117765A1 (en) 2005-11-18 2007-05-24 Cornell Research Foundation Inc. Nicotinoyl riboside compositions and methods of use
US20080242657A1 (en) 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
US20090192111A1 (en) 2007-12-01 2009-07-30 Asuragen, Inc. miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4739044A (en) 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IT1222414B (it) 1987-07-31 1990-09-05 Chiesi Farma Spa Composizioni farmaceutiche contenenti trapidil,loro procedimento di preparazione e relaticvo impiego terapeutico
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JPH02268185A (ja) * 1989-04-04 1990-11-01 Biogal Gyogyszergyar ５―メチル―７―（ジエチルアミノ）―Ｓ―トリアゾロ（１，５―ａ）ピリミジン及びその酸付加塩の製造方法
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
EP0604552B1 (en) 1991-09-18 1997-02-12 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
DE69233087T2 (de) 1991-11-22 2003-12-24 Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) Verfahren zur Herstellung von Polymerarrays
US5348853A (en) 1991-12-16 1994-09-20 Biotronics Corporation Method for reducing non-specific priming in DNA amplification
US5567583A (en) 1991-12-16 1996-10-22 Biotronics Corporation Methods for reducing non-specific priming in DNA detection
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
DE19514048A1 (de) * 1995-04-13 1996-10-17 Rentschler Arzneimittel Trapidil zur Verwendung in der Therapie von immunmodulatorisch beeinflußbaren Krankheitsbildern
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5869717A (en) 1997-09-17 1999-02-09 Uop Llc Process for inhibiting the polymerization of vinyl aromatics
JP2001521753A (ja) 1997-10-31 2001-11-13 アフィメトリックス インコーポレイテッド 成人臓器及び胎児臓器中の発現プロフィール
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2001322933A (ja) 2000-05-15 2001-11-20 Ucb Sa Ｃｄ４０シグナル遮断剤
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
CA2721797C (en) 2008-04-18 2018-02-27 Gary Zabow Magnetic microstructures for magnetic resonance imaging
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
KR101534395B1 (ko) 2013-08-01 2015-07-09 서울대학교산학협력단 트라피딜을 유효성분으로 포함하는 골 관련 질환의 예방 또는 치료용 조성물
WO2017059118A1 (en) * 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
WO2017117240A1 (en) 2015-12-29 2017-07-06 JONES AND MALTERER TECHNOLOGY INNOVATIONS INCORPORATED, d/b/a JAMTek Multi-point synchronizable and scalable lighting control systems
CA3054674A1 (en) * 2016-04-04 2017-12-10 Sinopia Biosciences, Inc. Treating extrapyramidal syndrome using trapidil
IL296788A (en) 2020-03-26 2022-11-01 Sinopia Biosciences Inc Isotopically labeled trepidil histories

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166972A1 (en) 2003-07-11 2006-07-27 Conn P J Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
US20080242657A1 (en) 2004-03-26 2008-10-02 Marino Michael J Treatment of Tremor with Histamine H3 Inverse Agonists or Hist Amine H3 Antagonists
US20070117765A1 (en) 2005-11-18 2007-05-24 Cornell Research Foundation Inc. Nicotinoyl riboside compositions and methods of use
US20090192111A1 (en) 2007-12-01 2009-07-30 Asuragen, Inc. miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention

Also Published As

Publication number Publication date
EP3442538A2 (en) 2019-02-20
CN116509869A (zh) 2023-08-01
AU2017246334A1 (en) 2018-11-15
JP2019510826A (ja) 2019-04-18
DK3442538T3 (da) 2025-09-01
JP7794668B2 (ja) 2026-01-06
FI3442538T3 (fi) 2025-09-04
US10350212B2 (en) 2019-07-16
US20230201205A1 (en) 2023-06-29
JP2024095682A (ja) 2024-07-10
US20180243307A1 (en) 2018-08-30
EP3442538B1 (en) 2025-07-23
EP3442538A4 (en) 2019-11-20
WO2017176652A3 (en) 2018-05-17
AU2017246334B2 (en) 2022-07-28
US12268691B2 (en) 2025-04-08
US20250387396A1 (en) 2025-12-25
WO2017176652A2 (en) 2017-10-12
JP2022088469A (ja) 2022-06-14
US20190328741A1 (en) 2019-10-31
AU2017246334C1 (en) 2022-11-17
US11628170B2 (en) 2023-04-18
ES3039958T3 (en) 2025-10-27
CN109310700A (zh) 2019-02-05
CA3054674A1 (en) 2017-12-10

Similar Documents

Publication Publication Date Title
JP7794668B2 (ja) トラピジルを使用する錐体外路症候群の処置
JP7832987B2 (ja) 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム
US11179375B2 (en) Methods and drug products for treating Alzheimer's disease
US20160243033A1 (en) Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
TW201605455A (zh) Ｂｅｔ抑制劑與布魯頓氏酪胺酸激酶抑制劑之組合
US20170354655A1 (en) Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations
JP2025111439A (ja) トラピジルを使用した認知障害の治療
BR112021010708A2 (pt) Formas cristalinas de um composto para tratar ou prevenir gota ou hiperuricemia
JP2015155422A (ja) ４−メチルピラゾールを使用してヒト対象を治療する遺伝子型特異的方法
WO2017011314A1 (en) Btk and hdac combinations
HK40004660B (en) Treating levodopa-induced dyskinesia using trapidil
HK40004660A (en) Treating levodopa-induced dyskinesia using trapidil
HK40047054A (en) Methods and systems for selection and treatment of patients with inflammatory diseases
HK40047054B (en) Methods and systems for selection and treatment of patients with inflammatory diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220318

R150 Certificate of patent or registration of utility model

Ref document number: 7049683

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250